A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-Reported Outcomes in Pediatric and Adult Patients With Eosinophilic Esophagitis (EoE), Gastritis (EoG), Enteritis (EoN) and Colitis (EoC)
A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-Reported Outcomes in Pediatric and Adult Patients With Eosinophilic Esophagitis (EoE), Gastritis (EoG), Enteritis (EoN) and Colitis (EoC)
The purpose of this observational study is to find the best measures to define how well a person with eosinophilic disorder is doing. People with EoE, EoG, EoN and EoC normally undergo endoscopy and/or colonoscopy where cells are collected for microscopic analysis. Treatments are then decided based on how the cells look. We are aiming to compare different tissue components such as inflammatory cell types with clinical symptoms. We want to see if scores on standard questionnaires can give us an idea how well the person is doing.
This is a longitudinal observational study in which individuals (males and females 3 years of age and greater) with EoE, EoG, EoN and EoC will be followed over the course of time to see if standard questionnaires can give us an idea of how well the person is doing.
Participants undergoing standard of care (normal, routine care) endoscopies and/or colonoscopies will have biopsies (small pieces of tissue from the GI tract normally collected during these procedures) collected and used for the research study. Participants will also complete questionnaires related to their symptoms and quality of life. Participants will be followed over the course of time and asked to complete the questionnaires at various time points throughout the study.
Inclusion Criteria:
EoE ≥ 15 eosinophils/HPF in the distal or proximal esophagus EoG ≥ 30 eosinophils/HPF in 5 HPF's in the body and/or antrum EoN ≥ 53 eosinophils/HPF in the duodenum and/or ≥ 56 eosinophils/HPF in the jejunum and/or ileum EoC ≥ 84 eosinophils/HPF from the transverse or descending colon and/or ≥ 32 eosinophils/HPF from the rectosigmoid colon or a biopsy from any colonic location with ≥ 100 eosinophils/HPF
- Presence of symptoms is required for patients who are newly diagnosed but not required for patients who were previously diagnosed.
Exclusion Criteria:
bliss.magella@cchmc.org513-636-7832
Phoenix, Arizona 85054, United States
nunez.renee@mayo.edu480-301-4992
Chicago, Illinois 60611, United States
CongletonAL@archildrens.org501-364-1060
kchaiboonma@health.ucsd.edu(858)-966-1700 ext. 226884
keanna.capener@cuanschutz.edu303-724-8974
rachel.andrews@childrenscolorado.org(720) 777-1994
tenesha.thomas@northwestern.edu
mriordan@luriechildrens.org312-227-4558
perla.adamescastillo@nih.gov
jaimie.gowatsky@mssm.edu212-241-4908
lucas_plott@med.unc.edu919-966-8559
bliss.magella@cchmc.org513-636-7832
delatorrei@chop.edu215-590-6187
Erin.Lee1@pennmedicine.upenn.edu215-662-2493
demarshm@mail.med.upenn.edu215-349-8546
regina.n.tyree@vumc.org(615) 343-6845
amandav@bcm.edu832-824-0939
dxtran1@texaschildrens.org(832)-824-3640
sophia.schuman@hsc.utah.edu801-585-0894